Complete Response Letter Sent to Citius for Its Lymphoma Drug Lymphir

Citius Pharmaceuticals’ BLA for its lymphoma drug Lymphir (denileukin diftitox) has hit a setback as the company has received a complete response letter (CRL) from the FDA requesting additional testing.
Source: Drug Industry Daily